Browsing: GLP1

With the help of exercise, a better diet, a lot of determination, and a GLP-1 medication, Jeanne Erland lost 164 pounds over two years

Although glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are highly effective for body weight reduction, there remains a critical unmet need for complementary strategies that drive selective fat loss and sustain long-term weight reduction. This study aimed to investigate whether Vutiglabridin, a novel oral small-molecule anti-obesity drug, complements GLP-1 RAs to enhance therapeutic efficacy by selectively…

As more consumers seek structured, provider-guided weight management support in 2026, this VivioMD GLP-1 review explores the platform’s advertised care experience, treatment-access process, pricing questions, and the factors that may make it appealing to patients ready to take a more active next step

ByDaniella Gray Newsweek is a Trust Project member See more of our trusted coverage when you search.to see more of our trusted coverage when you search.

July 15, 2026 ByLynne Christensen, Staff Writer

The GLP-1 conversation keeps expanding. We’ve covered Ozempic face, hair loss, muscle loss and what happens after you stop the medication. Now, a new NBER working paper by economist Rebecca Diamond, titled “GLP-1-Induced Weight Loss and the Female Obesity Penalty,” adds an uncomfortable new layer: GLP-1–related weight loss may also be linked to who lands…

The rapid rise in GLP-1 medication use has redefined consumers’ food expectations, panelists shared in a Tuesday IFT FIRST Hot Topics Studio session titled “GLP-1 and the Future of Food: Formulating for New Consumer Reality.”

– Millions of Medicare beneficiaries can now access GLP-1 weight-loss medication for $50 a month under a new option called the Medicare GLP-1 Bridge Program

Nearly two-fifths (37 per cent) of Canadian employers cover glucagon-like peptide-1 therapies for both diabetes and weight loss, up from 31 per cent in 2025 and just 17 per cent in 2024, according to a new survey by the International Foundation of Employee Benefit Plans

HealthDay News — The share of U.S. adults taking GLP-1 medications to lose weight has reached a record 11%